Omeros (STU:3O8) Short-Term Debt : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Omeros Short-Term Debt?

Omeros's Short-Term Debt for the quarter that ended in Mar. 2024 was €0.00 Mil.

Omeros's quarterly Short-Term Debt declined from Sep. 2023 (€88.93 Mil) to Dec. 2023 (€0.00 Mil) but then stayed the same from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€0.00 Mil).

Omeros's annual Short-Term Debt increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€89.10 Mil) but then declined from Dec. 2022 (€89.10 Mil) to Dec. 2023 (€0.00 Mil).

Omeros Short-Term Debt Historical Data

The historical data trend for Omeros's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Short-Term Debt Chart

Omeros Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

89.10

Omeros Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															88.31	87.44	88.93	-	-

Omeros Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Omeros Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Omeros's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Omeros (STU:3O8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (STU:3O8) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

OMER:USA 3O8:Germany

Address

201 Elliott Avenue West, Seattle, WA, USA, 98119

Website

https://www.omeros.com

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros (STU:3O8) Headlines

No Headlines